Dermira, Inc. Reports Consolidated Earnings Results for the First Quarter Ended March 31, 2017; Reiterates Earnings Guidance for the Year 2017
The company's management reiterated its previously issued financial guidance for full year 2017, including expected collaboration and license revenue of approximately $4.3 million and operating expenses of $165.0 million to $175.0 million, which includes estimated stock-based compensation expense of approximately $20.0 million.